Analysis of The Use of PCSK9 Inhibitors in Clinical Practice

Aim. The analysis of the experience of using PCSK9 inhibitors (alirocumab) in patients with very high cardiovascular risk, аccording to long observations in real clinical practice.Material and methods. In study evaluated the data for 31  people (23 men and 8 women, the average  age of those surveyed was 59.4±5.8 years) of very high cardiovascular risk with atherogenic dyslipidemia  and no achievement  of the target lipid levels. Alirokumab was administered  in a dose of 150 mg subcutaneously once every 2 weeks in the day hospital of a multidisciplinary clinic. The primary endpoint was reached the target level of low density lipoprotein cholesterol (HS-LDL) level and/or reduce HS-LDL levels by 50% or more. Liver tests, level of creatinine and glycemia  were studied to assess safety; side effects studied/Results. The long-term use of alirocumab  (on average 7,5±2,3 months) is well tolerated without adverse reactions and withdrawal syndrome, in the day hospital of a multidisciplinary clinic. 90% of patient have achieved either a target level of HS-LDL less than 1.4 mmol/l or a reduction in HS-LDL by 50% or more. The remaining  third of patients achieved both target levels. It can be distinguished a group of patients with a good response to the medication, in the first months of administration of alirokumab.Conclusion. The results of conducting an efficiency  assessment  for use of the alirocumab  in a dose of 150 mg  subcutaneously within two weeks showed  that this therapy has the high efficacy and good tolerability without any adverse reactions,  in the day hospital of a multidisciplinary clinic.